CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
AmyPore focuses on developing a novel treatment for neurodegenerative disorders by targeting amyloid protein oligomers. By utilizing artificial intelligence to optimize their drug candidate, AmyP53, they aim to block the formation of neurotoxic oligomers in brain cells, offering a new approach to these diseases.
Neurodegenerative disorders represent the most important medical, social and financial challenges for the 21st century.
In 2018, the world counts 50 million people with Alzheimer’s disease and 7 million with Parkinson’s disease, and the number of cases will double before 2050.
The current medical paradigms, which incriminate amyloid plaques as the main culprits of these pathologies, do not provide a cure or even stop the progression of the diseases.
All clinical trials based on anti-plaques immu…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
